Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

New research shows that 46% of generic drugs from the European Union (EU) critical list of medicines are supplied by just one provider.

Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...

A diversified supply of critical generic medicines from multiple manufacturers is required to ensure that healthcare systems can meet the needs of their patients. The research shows that for most ...

Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

E. Merck KG board of partners has announced the appointment of new CEOs to Merck KGaA’s executive board, aiding its ongoing ...

CyberArk’s market cap tops $20 billion as stock soars past $400, securing its spot as the second most valuable Israeli ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...